(024055-

# 9. 501(k) SUMMARY

## 9.1. Date:

DEC 2 0 2002

December 6, 2002

## 9.2. Submitted By:

TiSport, LLC 1426 East Third Avenue Kennewick, WA 99337 Phone: 509-586-6117 Fax: 509-586-2413

#### 9.3. Contact Person:

Richard S. Forman Vice President – Legal and Business Affairs TiSport, LLC 1426 East Third Avenue Kennewick, WA 99337

Phone: 509-586-6117, Ext. 238

Fax: 509-586-2413

## 9.4. Trade/Proprietary Name of Device:

TiLite Evo

## 9.5. Common Name of Device:

Manual, Rigid Wheelchair

## 9.6. Classification Name of Device:

Wheelchair, Mechanical (per 21 CFR section 890.3850)

## 9.7. Classification of Device:

Class I

#### 9.8. **Panel**:

Physical Medicine - Prosthetic Devices Subpart D – 890

## 9.9. Product Code:

89IOR

#### 9.10. Legally Marketed Predicate Device For Claimed Equivalence:

TiSport Cross-Sport (K990358)

## 9.11. Description of Device:

The TiLite Evo wheelchair is a rigid manual titanium wheelchair.

#### 9.12. Intended Use of the Device:

The intended use of this device (manual, rigid wheelchair) is the same as the predicate device. The intended use for the manual wheelchair is to provide mobility to physically impaired persons. The manual wheelchair is intended for ongoing daily use.

## 9.13. Target Population:

This device is indicated for individuals with the specific medical conditions listed, but the indications are not necessarily limited to such conditions:

- Amputee;
- Arthritis;
- Arthrogriposis;
- Cerebral Palsy;
- geriatric conditions;
- head injury or trauma;
- hemiplegic;
- Multiple Sclerosis;
- Muscular Dystrophy;
- paraplegic;
- Polio;
- quadraplegic;
- Spina Bifida;
- Stoke/CVA;
- tetraplegic; and
- other immobilizing or debilitating conditions, including spinal cord injuries and other lower and upper extremity paralysis

#### 9.14. Testing Results:

Meets the requirements of the ISO 7176 Parts 1, 3, 5, 7, and 8.

#### 9.15. Device Comparison:

The principal difference between the submitted device and the predicate device is that the TiLite Evo wheelchair is much more adjustable than the TiSport Cross-Sport wheelchair, which is primarily a non-adjustable custom wheelchair. The TiLite Evo is a custom wheelchair and its frame components are designed to be adjusted in a variety of

different ways by the user. For example, the TiLite Evo front and rear seat heights are adjustable. The TiLite Evo backrest height is adjustable. The TiLite Evo has an adjustable center of gravity. Of these features of the TiLite Evo that are adjustable, the TiSport Cross-Sport only has an adjustable center of gravity, and the mechanism to adjust the center of gravity is less user-friendly on the TiLite Cross-Sport.

Both the submitted device and the predicate device are made with titanium, whereas most rigid manual wheelchairs are made with aluminum. TiSport believes that titanium frames provide certain benefits when compared with aluminum frames from a safety perspective and a clinical perspective because of titanium's proven superior strength-to-weight ratio and its natural ability to absorb vibration.

Like the TiSport Cross-Sport, the TiLite Evo model offers a wide range of customization for the end user. TiSport believes that greater customization options allows for a better opportunity to properly "fit" the end user in a clinical setting as well as ensuring better safety and access to the chairs' options and accessories.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

DEC 2 0 2002

Tisport, LLC Richard S. Forman 1426 East Third Avenue Kennewick, Washington 99337-9669

Re: K024055

Trade/Device Name: TiLite Evo Regulation Number: 890.3850

Regulation Name: Wheelchair, mechanical

Regulatory Class: Class I

Product Code: IOR

Dated: December 6, 2002 Received: December 9, 2002

#### Dear Mr. Forman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in

the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Miriam C. Provost

Enclosure

# STATEMENT OF INDICATIONS FOR USE

# **Device Name:**

TiLite Evo

# Indication for Use:

The intended use of this device (manual, rigid wheelchair) is the same as the predicate device, the TiSport Cross-Sport (manual, rigid wheelchair) manufactured by TiSport, LLC. The intended use for the manual, rigid wheelchair is to provide mobility to physically persons. The manual wheelchair is intended for ongoing daily use

This device is indicated for individuals with the specific medical conditions listed, but the indications are not necessarily limited to such conditions:

- Amputee;
- Arthritis;
- Arthrogriposis;
- Cerebral Palsy;
- Geriatric conditions;
- Head injury or trauma;
- Hemiplegic;
- Multiple Sclerosis;
- Muscular Dystrophy;
- Paraplegic;
- Polio;
- Quadraplegic;
- Spina Bifida;
- Stoke/CVA;
- Tetraplegic; and
- Other immobilizing or debilitating conditions, including spinal cord injuries and other lower and upper extremity paralysis

Miriam C. Provost Division Sign-Off)

Division of General, Restorative

and Neurological Devices

10(k) Number K024055